Roche CEO Severin Schwan (AP Images)
Cancer giant Roche splashes into cell therapy with $3B+ Adaptimmune deal for off-the-shelf drugs
Despite its standing as pharma’s biggest cancer player, Roche has mostly stood pat on next-gen cell therapies that its competitors have gobbled up with gusto. Ready to finally make a splash of its own, Roche has inked a major deal to dive into the future.
Roche’s Genentech has signed a deal worth $150 million upfront and a total value of more than $3 billion to partner with Adaptimmune on off-the-shelf T cell therapies that marks the cancer giant’s first significant pipeline pivot into next-gen oncology drugs, the partners said Tuesday.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters